These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33146466)

  • 21. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases.
    Xu Z; Schlesinger D; Toulmin S; Rich T; Sheehan J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):612-8. PubMed ID: 22436795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between molecular subtypes and lymph node status in invasive breast cancer.
    Si C; Jin Y; Wang H; Zou Q
    Int J Clin Exp Pathol; 2014; 7(10):6800-6. PubMed ID: 25400761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
    Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
    Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
    Tseng YD; Uno H; Hughes ME; Niland JC; Wong YN; Theriault R; Blitzblau RC; Moy B; Breslin T; Edge SB; Hassett MJ; Punglia RS
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):622-30. PubMed ID: 26461004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
    BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival analysis of breast cancer subtypes in patients with spinal metastases.
    Wang M; Jensen AB; Morgen SS; Wu CS; Sun M; Li H; Dahl B; Bünger CE
    Spine (Phila Pa 1976); 2014 Sep; 39(19):1620-7. PubMed ID: 24979144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast carcinoma subtypes show different patterns of metastatic behavior.
    Molnár IA; Molnár BÁ; Vízkeleti L; Fekete K; Tamás J; Deák P; Szundi C; Székely B; Moldvay J; Vári-Kakas S; Szász MA; Ács B; Kulka J; Tőkés AM
    Virchows Arch; 2017 Mar; 470(3):275-283. PubMed ID: 28101678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
    Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
    Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
    Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
    Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
    Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.